AbbVie’s nearing $11B Apogee buyout sparks Oruka sympathy surge
Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002. The company's main operations are based in Menlo Park, CA.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $27.00K | $111.00K | $114.00K | $91.00K | $93.00K | $89.00K | $22.00K | $27.00K |
| Gross Profit | $-27.00K | $-111.00K | $-114.00K | $-91.00K | $-93.00K | $-89.00K | $-22.00K | $-27.00K |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $88.10M | $7.18M | $9.73M | $19.24M | $9.67M | $5.72M | $8.10M | $18.68M |
| Operating Income | $-88.12M | $-7.30M | $-9.84M | $-19.34M | $-9.77M | $-5.81M | $-8.12M | $-18.71M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income | $-83.72M | $-5.34M | $-9.93M | $-19.32M | $-9.74M | $-5.48M | $-7.93M | $-18.49M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-4.99 | $-4.44 | $-8.27 | $-16.68 | $-8.40 | $-49.79 | $-123.73 | $-382.87 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |